One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide markedly im...
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide markedly improves 24-h glycemia and [alpha]- and [beta]-cell function and reduces endogenous glucose release in patients with type 2 diabetes
About this item
Full title
Author / Creator
Publisher
New York: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
New York: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2 diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell hormone profiles, and gastric emptying during meals using acetaminophen....
Alternative Titles
Full title
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide markedly improves 24-h glycemia and [alpha]- and [beta]-cell function and reduces endogenous glucose release in patients with type 2 diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_216488623
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_216488623
Other Identifiers
ISSN
0012-1797
E-ISSN
1939-327X
